|Concomitant angiosarcoma and lymphoproliferative disorder in solid organ ...|
An increased risk of posttransplant malignancy has been consistently reported following various solid organ transplants. The malignancies most commonly encountered are non-melanoma skin cancers, carcinomas of lung or breast and posttransplant ...
7thSpace Interactive (press release) - Fri, 31 Oct 2014 02:45
|Genzyme CEO: Lemtrada's 'unique profile' raises new questions around MS|
The FDA approval came with a black box warning of "sometimes fatal autoimmune conditions, serious and life-threatening infusion reactions and ... an increased risk of malignancies including thyroid cancer, melanoma and lymphoproliferative disorders.
Boston Business Journal (blog) - Mon, 17 Nov 2014 11:41
|Genzyme's MS Drug Lemtrada Approved by the FDA|
Multiple Sclerosis News Today - Mon, 17 Nov 2014 10:54
|Sanofis Lemtrada Gets U.S. Approval, Carries Boxed Warning|
Zacks.com - Mon, 17 Nov 2014 13:27
|Sanofi persuades FDA to back its MS drug Lemtrada|
PMLiVE - Mon, 17 Nov 2014 03:59
|Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing ...|
News-Medical.net - Fri, 14 Nov 2014 17:52
|Computational approaches may expedite drug repurposing for rare diseases|
Analysing the language in the abstracts allowed the researchers to build visual networks linking different types of node, such as disease, protein, biological process, or drug. To show how these networks ... Indeed, there have been a number of ...
ScienceBlog.com (blog) - Fri, 21 Nov 2014 00:37
|Genzyme's Lemtrada Approved by the FDA|
Lemtrada may be associated with an increased risk of malignancy, including thyroid cancer, melanoma and lymphoproliferative disorders. The Lemtrada REMS Program, a comprehensive risk management program with frequent monitoring, is being ...
Rock Hill Herald (press release) - Fri, 14 Nov 2014 17:52
|FDA reverses an embarrassing rejection of Sanofi's Lemtrada, OKs MS drug|
FierceBiotech - Sat, 15 Nov 2014 12:53
|FDA Approval for Alemtuzumab (Lemtrada) in MS|
Medscape - Sat, 15 Nov 2014 07:11
|US okays Sanofi MS drug at last|
PharmaTimes - Sun, 16 Nov 2014 16:56
|FDA Approves Alemtuzumab for Relapsing Forms of Multiple Sclerosis|
HCPLive - Sat, 15 Nov 2014 08:41
|FDA at last approves Genzyme's Lemtrada|
The Pharma Letter - Sat, 15 Nov 2014 07:00
|Selective, efficient modulation of activated CD4+ αβT cells by the novel ...|
... is associated with severe side effects such as cytokine release syndrome, pulmonary oedema, aseptic meningitis and EBV-related post-transplant lymphoproliferative disease.15, 16, 17, 18 Although preemptive corticosteroids mitigate some of these ...
Nature.com - Mon, 17 Nov 2014 08:34
|FDA Okays Sanofi's Lemtrada For Treatment Of Multiple Sclerosis|
... noting a risk of serious, sometimes fatal autoimmune conditions, serious and life-threatening infusion reactions and also noting Lemtrada may cause an increased risk of malignancies including thyroid cancer, melanoma and lymphoproliferative disorders.
RTT News - Sun, 16 Nov 2014 17:52
|The Invisible Revolution|
... response as a tracer of depth of remission either by flow negative complete remission (CR) in chronic lymphocytic leukemia or molecular CR in lymphomas or leukemia, which likely will become the next endpoint in most lymphoproliferative disorders.
OncLive - Tue, 11 Nov 2014 13:11
|Hepatitis C Virus Infection and Kidney Transplantation in 2014|
Chronic hepatitis C virus (HCV) infection remains an important health problem, which is associated with deleterious consequences in kidney transplant recipients. Besides hepatic complications, several extrahepatic complications contribute to reduced ...
Medscape - Mon, 10 Nov 2014 21:03